Skin Cancer: From Molecular Basis to Therapy: 2nd Edition

Dear Colleagues,

The second volume of this Special Issue follows on from the success of the first one. With that said, we invite you to publish your research in this edition of “Skin Cancer: From Molecular Basis to Therapy” (https://www.mdpi.com/journal/life/special_issues/3GWP9E18Z8).

Keratinocyte tumors, commonly referred to as nonmelanoma skin cancer (NMSC), constitute a heavy burden of disease, being the leading malignancy in terms of frequency for Caucasian individuals. Specifically, in subjects with lighter skin phototypes, basal cell carcinoma (BCC) is the most common cancer. On the other hand, melanoma is a global health concern, being among the most common malignancies responsible for years of life lost in young adults. Additionally, rarer types of cancer arise in the skin: cutaneous lymphomas are a group of malignant lymphocyte proliferations that feature striking skin homing even during dissemination, which sets them apart from nodal forms of lymphoma. Finally, Kaposi sarcoma is a multifocal systemic disease that challenges the traditional dogma of cancer clonality.

This Special Issue welcomes contributions that highlight a multidisciplinary approach to the diagnosis and management of skin cancer, and will focus on the following:

• Basic science research providing novel insights into signal transduction pathways in cutaneous carcinogenesis and the role of “mutator phenotypes” in individuals with hereditary tumor predisposition syndromes;
• Recent updates in the early detection of skin cancers and strategies aimed at reducing UV radiation exposure;
• Innovative approaches in surgical or skin-directed treatments for skin cancer.

While the breakthrough therapies that have revolutionized the management of advanced skin cancer are beyond the current scope, contributions emphasizing the significance of a multidisciplinary approach in this setting, as well as patients’ perspectives, are an appreciated addition to this collection.

This Special Issue is now open for the submission of new research papers and reviews. Prospective contributors are encouraged to share a brief abstract or provisional title with the Editorial Office to discuss with the editors.

Dr. Alvise Sernicola
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• nonmelanoma skin cancer
• melanoma
• cutaneous lymphoma
• Kaposi sarcoma
• skin-directed therapy
• carcinogenesis
• UV radiation
• tumor predisposition syndrome